Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas.

ABSTRACT:

Background

This phase II clinical trial evaluated the safety and efficacy of nilotinib in patients with recurrent, platelet-derived growth factor receptor alpha (PDGFRA)-enriched high-grade gliomas.

Methods

Thirty-four adult patients with PDGFRA-enriched recurrent high-grade gliomas were enrolled. Study treatment consisted of nilotinib 400 mg administered twice daily in 28-day cycles. Safety and clinical activity were evaluated.

Results

Median lines of prior therapy were 2 (range 1-7) and 9 of 34 (26%) patients received prior bevacizumab. Four patients had PDGFRA gene amplification, and 30 had PDGFRA overexpression by immunohistochemistry. Overall, nilotinib was well tolerated. The most common treatment-related toxicities were increased ALT, joint pain, and hyp

SUBMITTER: Piccioni D 

PROVIDER: S-EPMC12288025 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature